Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 20, 2013, Pages 8170-8175

  Mahlknecht, Georg ^a   Maron, Ruth ^a   Mancini, Maicol ^a   Schechter, Bilha ^a   Sela, Michael ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STOMACH CANCER; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELL PROLIFERATION; CROSS-LINKING REAGENTS; CYTOPLASM; DNA; FEMALE; HUMANS; LYSOSOMES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEOTIDES; PROTEIN BINDING; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84877854501     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1302594110     Document Type: Article

References (26)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137. (Pubitemid 33674041)
2. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11):1160-1174.
3. Stoltenburg R, Reinemann C, Strehlitz B (2007) SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 24(4):381-403. (Pubitemid 47391579)
4. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968):505-510.
5. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346(6287):818-822.
6. Tombelli S, Minunni M, Mascini M (2005) Analytical applications of aptamers. Biosens Bioelectron 20(12):2424-2434. (Pubitemid 40602182)
7. Guo KT, Ziemer G, Paul A, Wendel HP (2008) CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci 9(4):668-678. (Pubitemid 351631122)
8. Famulok M, Mayer G (2011) Aptamer modules as sensors and detectors. Acc Chem Res 44(12):1349-1358.
9. Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM (1999) Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 274(37): 26369-26377.
10. Li N, Nguyen HH, Byrom M, Ellington AD (2011) Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS ONE 6(6):e20299.
11. Dastjerdi K, Tabar GH, Dehghani H, Haghparast A (2011) Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol Appl Biochem 58(4):226-230.
12. Esposito CL, et al. (2011) A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6(9):e24071.
13. Kim MY, Jeong S (2011) In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther 21(3):173-178.
14. Chen CH, Chernis GA, Hoang VQ, Landgraf R (2003) Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA 100(16):9226-9231. (Pubitemid 37033911)
15. Dassie JP, et al. (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27(9):839-849.
16. Zwang Y, Yarden Y (2009) Systems biology of growth factor-induced receptor endocytosis. Traffic 10(4):349-363.
17. Klapper LN, Waterman H, Sela M, Yarden Y (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60(13):3384-3388. (Pubitemid 30482151)
18. Kasprzyk PG, Song SU, Di Fiore PP, King CR (1992) Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52(10):2771-2776.
19. Flanagan JG, Leder P (1988) neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation. Proc Natl Acad Sci USA 85(21):8057-8061.
20. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M (2009) Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci USA 106(9):3294-3299.
21. Friedman LM, et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 102(6):1915-1920. (Pubitemid 40261987)
22. Spangler JB, et al. (2010) Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci USA 107(30):13252-13257.
23. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443-446. (Pubitemid 30208162)
24. Farokhzad OC, et al. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103(16):6315-6320.
25. Missailidis S (2003) Targeting of antibodies using aptamers. Antibody Engineering: Methods and Protocols, ed Lo BKC (Humana, Totowa, NJ), Vol 51, pp 547-555.
26. Crameri A, Stemmer WP (1993) 10(20)-fold aptamer library amplification without gel purification. Nucleic Acids Res 21(18):4410. (Pubitemid 23279050)